H.C. Wainwright Reiterates Buy Rating on Mirum Pharamceuticals (MIRM), 'affirm MIRM shares as one of our 2024 Top Picks'
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $66.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
